Development of an academic disease registry for spinal muscular atrophy

•We report the development of the new disease registry: International SMA Registry.•The aim was to establish a system for collection of highly curated data.•The paper describes the development of the registry and its final version.•Over 800 patients have been collected since June 2018.•The registry...

Full description

Saved in:

Bibliographic Details
Published in:	Neuromuscular disorders : NMD Vol. 29; no. 10; pp. 794 - 799
Main Authors:	Mercuri, Eugenio, Finkel, Richard, Scoto, MariaCristina, Hall, Susan, Eaton, Susan, Rashid, Aisha, Balashkina, Julia, Coratti, Giorgia, Pera, Maria Carmela, Samsuddin, Salma, Civitello, Matthew, Muntoni, Francesco, De Vivo, Darryl C, Darras, Basil T, Day, John, Montes, Jacqueline, Glanzmann, Allan, Pasternack, Amy, Salazar, Rachel, Dunaway Young, Sally, Duong, Tina, Pane, Marika, Berti, Beatrice, Palermo, Concetta, Leone, Daniela, Frongia, Annalia, Antonaci, Laura, De Sanctis, Roberto, Messina, Sonia, Bertini, Enrico, Vita, Giuseppe, Bruno, Claudio, Sframeli, Maria, Sansone, Valeria A, Albamonte, Emilio, D'Amico, Adele
Format:	Journal Article
Language:	English
Published:	England Elsevier B.V 01-10-2019
Subjects:	Disease registry Neuromuscular disorders Spinal muscular atrophy Disease registry Neuromuscular disorders Spinal muscular atrophy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•We report the development of the new disease registry: International SMA Registry.•The aim was to establish a system for collection of highly curated data.•The paper describes the development of the registry and its final version.•Over 800 patients have been collected since June 2018.•The registry will be of help in conducting studies on large cohort of patients. We report the development of a new disease registry on SMA as the result of a collaboration among three national networks in United States, Italy, and United Kingdom in partnership with a biotechnology company and with the support of advocacy groups. The aim of establishing a large collaborative registry within academic centers was to establish a structured but flexible system for collection of prospective, highly curated data that will deeply phenotype all patients with SMA and follow them longitudinally over several years. This paper describes the process leading to the development of the registry including the identification of the relevant data elements, the design of an electronic CRF with a shared data dictionary, the piloting of the first version and the definition of the final version. The registry will provide a central structure for conducting academic studies based on a much larger cohort of patients than those available in the individual networks. Due to the quality control of the data collected the registry can also be used for postmarketing purposes, allowing to share, in a transparent and controlled way, real-world data with pharmaceutical partners, drug regulatory agencies, and advocacy groups for better understanding of safety and effectiveness of new treatments.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0960-8966 1873-2364
DOI:	10.1016/j.nmd.2019.08.014